The ANA Screening test is a solid-phase chemiluminescent immunoassay (ChLIA) designed for the initial antibody profile screening in ANA-positive patients, providing a first level of characterisation before more specific testing. It serves as a confirmation test following indirect immunofluorescence on HEp-2 cells (IIF), improving diagnostic selectivity and reducing false positives.
Each magnetic particle is coated with a mix of key antigens associated with SARD. The antigen mix is designed to cover the main autoantibody specificities linked to SLE, systemic sclerosis, Sjögren’s syndrome, myositis and overlap syndromes. In particular:
- U1-snRNP (70 kDa, A and C) and Sm for SLE and MCTD
• SS-A/Ro (60 kDa and 52 kDa) and SS-B/La for Sjögren’s syndrome, SLE, and myositis
• Scl-70 for systemic sclerosis (diffuse and overlap forms)
• Jo-1 for anti-synthetase syndrome
• CENP-B for limited SSc
• dsDNA for SLE
Serum, EDTA plasma
ChLIA
Fasting for at least 8-12 hours before sampling
Refer to the Health Service Charter to check storage conditions
+2/+8°C
This test provides the quantitative determination of total tau protein to support the diagnosis of Alzheimer’s disease.
This test provides the quantitative determination of tau protein phosphorylated at threonine 181 (pTau181), to support the diagnosis of Alzheimer’s disease.
Test for the determination of human autoantibodies against NMDAR to support the diagnosis of paraneoplastic neurological syndromes with an intermediate-risk phenotype.
Subscribe to our newsletter to be always updated.